Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 1:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Celecoxib Clear all
Terminated No phase listed Observational

Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib

NCT00320918
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Sep 16, 2026, 1:44 AM EDT
Completed Phase 4 Interventional

Effect of Celecoxib Versus Placebo Before and After Knee Surgery on the Overall Use of Analgesics After Surgery

NCT00633386
View directory record Official record
Conditions
Arthroscopy
Interventions
Celecoxib, Placebo
Drug · Other
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
9
States / cities
Phoenix, Arizona • St. Petersburg, Florida • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 16, 2026, 1:44 AM EDT
Not yet recruiting Phase 2 Interventional

SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction

NCT07597902
View directory record Official record
Conditions
Post-acute Sequelae of COVID-19, Long COVID
Interventions
Valacyclovir, Celecoxib, Paxlovid, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 16, 2026, 1:44 AM EDT
Completed Phase 3 Interventional Results available

Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement

NCT02674386
View directory record Official record
Conditions
Osteoarthritis
Interventions
Investigational Medical Product (IMP) administered in parent study
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
51
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Sep 16, 2026, 1:44 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

NCT05756166
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy, Biospecimen Collection, Celecoxib, Computed Tomography, Interferon Alpha-2, Magnetic Resonance Imaging, Pembrolizumab, Rintatolimod
Procedure · Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 16, 2026, 1:44 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis

NCT00154219
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Lumiracoxib (drug)
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Sep 16, 2026, 1:44 AM EDT
Completed Phase 2 Interventional

Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer

NCT00258232
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, celecoxib, irinotecan hydrochloride
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
3
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2013 · Synced Sep 16, 2026, 1:44 AM EDT
Terminated Phase 1 Interventional

Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer

NCT00177853
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
celecoxib, irinotecan, concurrent radiotherapy
Drug · Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2010 · Synced Sep 16, 2026, 1:44 AM EDT
Completed Phase 3 Interventional

Anti-Inflammatory Treatment for Age-Associated Memory Impairment: A Double-Blind Placebo-Controlled Trial

NCT00009230
View directory record Official record
Conditions
Memory Disorders
Interventions
Celecoxib
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 16, 2026, 1:44 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Variability in Response to Non-steroidal Anti-inflammatory Drugs

NCT02502006
View directory record Official record
Conditions
Healthy
Interventions
Celecoxib, Naproxen, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 16, 2026, 1:44 AM EDT
Completed No phase listed Observational

Evaluation of Post Hospital Administration of Celecoxib Following Minimally Invasive Knee Replacement Surgery

NCT00474773
View directory record Official record
Conditions
Pain Management, Function, Minimally Invasive Total Knee Arthroplasty, Celecoxib
Interventions
Celecoxib
Drug
Lead sponsor
St. Louis Joint Replacement Institute
Other
Eligibility
Not listed
Enrollment
107 participants
Timeline
2007 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Sep 16, 2026, 1:44 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Indomethacin Capsules to Treat Dental Pain

NCT00964431
View directory record Official record
Conditions
Dental Pain
Interventions
Celecoxib 400 mg, Placebo, Indomethacin Test (lower dose), Indomethacin Test (upper dose)
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Sep 16, 2026, 1:44 AM EDT
Terminated Phase 2 Interventional

Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases

NCT00080782
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
Celecoxib, Doxorubicin Hydrochloride, Strontium chloride Sr 89
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 16, 2026, 1:44 AM EDT
Completed Phase 4 Interventional Results available

Opioid-Free Shoulder Arthroplasty

NCT03540030
View directory record Official record
Conditions
Opioid Use, Shoulder Osteoarthritis, Avascular Necrosis, Rotator Cuff Tear, Arthritis;Inflammatory
Interventions
Gabapentin, Celecoxib, toradol, acetaminophen, regional block, propofol, IV lidocaine, rocuronium, vecuronium, sevoflurane, desflurane
Drug
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
50 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 16, 2026, 1:44 AM EDT
Withdrawn Phase 4 Interventional

Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients

NCT02160301
View directory record Official record
Conditions
Post Operative Pain Control
Interventions
Gabapentin, Acetaminophen, Celecoxib, Dexamethasone, Oxycodone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Sep 16, 2026, 1:44 AM EDT
Completed Phase 1 Interventional

Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery

NCT00450736
View directory record Official record
Conditions
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Interventions
celecoxib, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 16, 2026, 1:44 AM EDT
Completed Phase 1 Interventional

Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2

NCT00400374
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Erlotinib, Celecoxib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Sep 16, 2026, 1:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women

NCT00056082
View directory record Official record
Conditions
Breast Cancer
Interventions
celecoxib
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2013
U.S. locations
3
States / cities
Chicago, Illinois • Kansas City, Kansas • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Sep 16, 2026, 1:44 AM EDT
Terminated Phase 4 Interventional Results available

NSAIDs vs. Coxibs in the Presence of Aspirin

NCT03699293
View directory record Official record
Conditions
Rheumatoid Arthritis, Cardiovascular Diseases
Interventions
celecoxib 200mg capsule, naproxen sodium 550mg tablet, Aspirin 81mg tablet
Drug
Lead sponsor
Platelet and Thrombosis Research, LLC
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 16, 2026, 1:44 AM EDT
Completed Phase 4 Interventional Results available

Early Diuresis Following Colorectal Surgery

NCT02351934
View directory record Official record
Conditions
Colorectal Disorders
Interventions
Furosemide, Celecoxib, Gabapentin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 16, 2026, 1:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers

NCT02099136
View directory record Official record
Conditions
No Evidence of Disease
Interventions
UV Light Therapy, Placebo, Celecoxib, Biopsy, Imaging Biomarker Analysis
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 16, 2026, 1:44 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen

NCT00638807
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Celecoxib, Placebo
Drug · Other
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
33
States / cities
Birmingham, Alabama • Buena Park, California • Denver, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 16, 2026, 1:44 AM EDT
Completed Phase 4 Interventional

Effect of Celecoxib on Markers of Vascular Inflammation

NCT00471341
View directory record Official record
Conditions
Hypertension and Coronary Artery Disease
Interventions
Celecoxib, placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
50 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
Gainesville, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2011 · Synced Sep 16, 2026, 1:44 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Photodynamic Therapy-Induced Immune Modulation: Part III

NCT03643744
View directory record Official record
Conditions
Actinic Keratosis, Photodynamic Therapy
Interventions
Celecoxib 200mg, Placebo
Drug
Lead sponsor
Wright State University
Other
Eligibility
45 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 16, 2026, 1:44 AM EDT